Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis by Hoogman, M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/169834
 
 
 
Please be advised that this information was generated on 2019-12-04 and may be subject to
change.
310 www.thelancet.com/psychiatry   Vol 4   April 2017
Articles
Lancet Psychiatry 2017; 
4: 310–19
Published Online 
February 15, 2017 
http://dx.doi.org/10.1016/
S2215-0366(17)30049-4
This online publication 
has been corrected. 
The corrected version 
first appeared at 
thelancet.com/psychiatry on 
May 8, 2017
See Comment page 266
Department of Human Genetics 
(M Hoogman PhD, J Bralten PhD, 
K J E van Hulzen PhD, 
E Shumskaya PhD, T Wolfers MSc, 
A M H Onnink PhD, 
J C Mostert PhD, 
Prof B Franke PhD), Department 
of Psychiatry (J T Dammers MSc, 
N Rommelse PhD, Prof B Franke), 
and Department of Cognitive 
Neuroscience 
(Prof J K Buitelaar PhD), Radboud 
University Medical Center, 
Nijmegen, Netherlands; 
Donders Institute for Brain, 
Cognition and Behaviour, 
Nijmegen, Netherlands 
(M Hoogman, J Bralten, 
M P Zwiers PhD, M Mennes PhD, 
K J E van Hulzen, E Shumskaya, 
A M H Onnink, J T Dammers, 
Prof J K Buitelaar, Prof B Franke, 
T Wolfers, J C Mostert); Imaging 
Genetics Center, Mark and Mary 
Stevens Institute for 
Neuroimaging and Informatics, 
Keck School of Medicine of USC, 
University of Southern 
California, Marina del Rey, CA, 
USA (D P Hibar PhD, 
N Jahanshad PhD, 
Prof P M Thompson PhD); 
Department of Psychiatry,
Subcortical brain volume differences in participants with 
attention deficit hyperactivity disorder in children and 
adults: a cross-sectional mega-analysis
Martine Hoogman, Janita Bralten, Derrek P Hibar, Maarten Mennes, Marcel P Zwiers, Lizanne S J Schweren, Kimm J E van Hulzen, 
Sarah E Medland, Elena Shumskaya, Neda Jahanshad, Patrick de Zeeuw, Eszter Szekely, Gustavo Sudre, Thomas Wolfers, Alberdingk M H Onnink, 
Janneke T Dammers, Jeanette C Mostert, Yolanda Vives-Gilabert, Gregor Kohls, Eileen Oberwelland, Jochen Seitz, Martin Schulte-Rüther, 
Sara Ambrosino, Alysa E Doyle, Marie F Høvik, Margaretha Dramsdahl, Leanne Tamm, Theo G M van Erp, Anders Dale, 
Andrew Schork, Annette Conzelmann, Kathrin Zierhut, Ramona Baur, Hazel McCarthy, Yuliya N Yoncheva, Ana Cubillo, Kaylita Chantiluke, 
Mitul A Mehta, Yannis Paloyelis, Sarah Hohmann, Sarah Baumeister, Ivanei Bramati, Paulo Mattos, Fernanda Tovar-Moll, Pamela Douglas, 
Tobias Banaschewski, Daniel Brandeis, Jonna Kuntsi, Philip Asherson, Katya Rubia, Clare Kelly, Adriana Di Martino, Michael P Milham, 
Francisco X Castellanos, Thomas Frodl, Mariam Zentis, Klaus-Peter Lesch, Andreas Reif, Paul Pauli, Terry L Jernigan, Jan Haavik, Kerstin J Plessen, 
Astri J Lundervold, Kenneth Hugdahl, Larry J Seidman, Joseph Biederman, Nanda Rommelse, Dirk J Heslenfeld, Catharina A Hartman, 
Pieter J Hoekstra, Jaap Oosterlaan, Georg von Polier, Kerstin Konrad, Oscar Vilarroya, Josep Antoni Ramos-Quiroga, Joan Carles Soliva, 
Sarah Durston, Jan K Buitelaar, Stephen V Faraone, Philip Shaw, Paul M Thompson, Barbara Franke
Summary
Background Neuroimaging studies have shown structural alterations in several brain regions in children and adults 
with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD 
Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate 
sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in 
children and adults with ADHD compared with those without this diagnosis.
Methods In this cross-sectional mega-analysis, we used the data from the international ENIGMA Working Group 
collaboration, which in the present analysis was frozen at Feb 8, 2015. Individual sites analysed structural T1-weighted 
MRI brain scans with harmonised protocols of individuals with ADHD compared with those who do not have this 
diagnosis. Our primary outcome was to assess case-control differences in subcortical structures and intracranial 
volume through pooling of all individual data from all cohorts in this collaboration. For this analysis, p values were 
significant at the false discovery rate corrected threshold of p=0·0156.
Findings Our sample comprised 1713 participants with ADHD and 1529 controls from 23 sites with a median age of 
14 years (range 4–63 years). The volumes of the accumbens (Cohen’s d=–0·15), amygdala (d=–0·19), caudate 
(d=–0·11), hippocampus (d=–0·11), putamen (d=–0·14), and intracranial volume (d=–0·10) were smaller in individuals 
with ADHD compared with controls in the mega-analysis. There was no difference in volume size in the pallidum 
(p=0·95) and thalamus (p=0·39) between people with ADHD and controls. Exploratory lifespan modelling suggested 
a delay of maturation and a delay of degeneration, as effect sizes were highest in most subgroups of children 
(<15 years) versus adults (>21 years): in the accumbens (Cohen’s d=–0·19 vs –0·10), amygdala (d=–0·18 vs –0·14), 
caudate (d=–0·13 vs –0·07), hippocampus (d=–0·12 vs –0·06), putamen (d=–0·18 vs –0·08), and intracranial volume 
(d=–0·14 vs 0·01). There was no difference between children and adults for the pallidum (p=0·79) or thalamus 
(p=0·89). Case-control differences in adults were non-significant (all p>0·03). Psychostimulant medication use 
(all p>0·15) or symptom scores (all p>0·02) did not influence results, nor did the presence of comorbid psychiatric 
disorders (all p>0·5).
Interpretation With the largest dataset to date, we add new knowledge about bilateral amygdala, accumbens, and 
hippocampus reductions in ADHD. We extend the brain maturation delay theory for ADHD to include subcortical 
structures and refute medication effects on brain volume suggested by earlier meta-analyses. Lifespan analyses 
suggest that, in the absence of well powered longitudinal studies, the ENIGMA cross-sectional sample across 
six decades of ages provides a means to generate hypotheses about lifespan trajectories in brain phenotypes.
Funding National Institutes of Health.
Introduction
Attention deficit hyperactivity disorder (ADHD) is a 
common neuropsychiatric disorder with a prevalence 
of 5·3% in childhood (younger than 18 years old).1 
Two-thirds of patients with an ADHD diagnosis in 
childhood continue to have persistent, impairing 
symptoms in adulthood.2 ADHD is character ised by age-
inappropriate symptoms of inattention or hyper activity 
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and impulsivity.3 Many imaging studies, often in small 
samples, have reported brain structural and functional 
differences between individuals with ADHD and 
controls, both in childhood and adulthood. Five meta-
analyses of structural neuroimaging studies in patients 
with ADHD have been published (appendix). One meta-
analysis pooled region-of-interest brain volume studies,4 
whereas the others pooled voxel-based morphometry 
studies.5–8 The most consistent results across studies 
were for reduced volumes of (parts of) the basal ganglia 
for patients compared with healthy controls. Two meta-
analyses showed that, with increasing age, basal ganglia 
structural differences between individuals with ADHD 
and controls tended to decrease, and that stimulant 
treatment was associated with healthy volumes of these 
brain structures.5,6
Altered brain volumes have also been associated with 
clinical features of ADHD; smaller volumes of caudate, 
cerebellum, and frontal and temporal gray matter have 
been associated with greater symptom severity.9 Also in 
the general population, ADHD symptoms correlated 
with volumetric brain measures.10,11
Identification of structural brain differences in people 
with ADHD is important to further insights into the 
neural substrates of ADHD. So far, analyses of brain 
structures in ADHD have been small in size 
and statistical power (appendix); the sample size of 
the largest published meta-analysis of brain volume 
(565 cases and 583 controls) allowed for the 
identification of differences in brain volume with 
Cohen’s d effect sizes of 0·15 or higher with 80% power 
(G*Power, version 3.1). Analyses of other psychiatric 
disorders show that smaller effects are likely.12 Existing 
meta-analyses for ADHD only used published data as 
source material, which limited their ability to address 
covariates that might vary among studies, such as 
age and medication.5,6 Additionally, the existing 
meta-analyses included studies with variable methods 
and protocols such as the segmentation software and 
quality control.
To overcome such limitations and to do collaborative 
studies of maximal power, we founded the ENIGMA 
ADHD Working Group in 2013 to aggregate structural 
MRI data from participants with ADHD and healthy 
controls across the lifespan. This worldwide collaboration 
enabled analyses of existing individual data, improving 
on earlier meta-analyses by basing analyses on the use of 
harmonised segmentation and quality control protocols. 
Our increased sample size compared with all earlier 
studies supported both mega-analysis and meta-analysis 
(appendix) designs across 60 years of the lifespan. We 
selected subcortical brain volumes as our target, because 
of neurodevelopmental theories hypothesising that 
ADHD is linked to early-emerging, persistent subcortical 
abnormalities,13 and building on the results of earlier 
meta-analyses,4–8 which showed that deviations in these 
subcortical volumes were most consistently observed. 
Additionally, we investigated intracranial volume as a 
measure of total brain volume. The mega-analysis 
design allowed investigation of associations with 
Research in context
Evidence before this study
We searched PubMed from the start of the database until 
Feb 1, 2015, for meta-analyses of brain volume differences in 
patients with attention deficit hyperactivity disorder (ADHD), 
including the subcortical regions, with the search terms “ADHD”, 
“structural”, “brain”, and “meta-analysis [Title]”, and “English” 
[Language]. We found four published meta-analyses before we 
started the study. The largest dataset of those meta-analyses 
was of 565 cases and 583 controls (children only—ie, individuals 
younger than 18 years). The published meta-analyses had 
three major limitations: the power was only sufficient to detect 
effect sizes of Cohen’s d of 0·15 and higher, which we know to be 
insufficient on the basis of results in other psychiatric disorders; 
they used only published data as source material, which limited 
their ability to address covariates that might vary among 
studies, such as age and medication; and they included studies 
with different segmentation software and quality control 
procedures, contributing to heterogeneity across samples.
Added value of this study
The present multisite study, with data of 1713 cases and 
1529 controls, is the largest and best-powered study to date 
on brain volumes in patients with ADHD. Data for all sites 
were newly analysed with harmonised methods. Our work 
implicates new structural differences in patients with ADHD in 
the amygdala and hippocampus, and provides unprecedented 
precision in effect size estimates. Our results, covering most 
of the lifespan, showed that the most pronounced effects 
were in childhood.
Implications of all the available evidence
We confirm, with high-powered analysis, that patients with 
ADHD have altered brains; therefore ADHD is a disorder of the 
brain. This message is clear for clinicians to convey to parents 
and patients, which can help to reduce the stigma of ADHD and 
improve understanding of the disorder. As for major depressive 
disorder, for example, clinicians can label ADHD as a brain 
disorder. Also, finding the most pronounced effects in 
childhood provides a relevant model of ADHD as a disorder of 
brain maturation delay. Finding the biggest effect in the 
amygdala is another important message because this area links 
ADHD to emotional regulation problems. Those symptoms are 
frequently reported in patients with ADHD but have not (yet) 
made it into the official DSM criteria. Our work shows 
neurobiological support for the inclusion of emotional 
regulation in the core ADHD phenotype.
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symptom scores, age, psychostimulant medication use, 
and comorbidity with other psychiatric disorders.
Methods
Study design
This cross-sectional mega-analysis was done with the 
ENIGMA ADHD Working Group; details about the 
diagnostic procedures for each site are listed in the 
appendix. The group adopted a rolling inclusion design, 
in which new groups can join at any time, but data 
freezes allowed for analysis at fixed timepoints. The 
data freeze for the present subcortical analysis was set 
at Feb 8, 2015. Each participating site had approval 
from its local ethics committee to do the study and to 
share de-identified, anonymised individual data. Part of 
the protocol is published online. 
Neuroimaging
Structural T1-weighted brain MRI data were acquired and 
processed at the individual sites. The images were analysed 
with standardised protocols to harmonise analysis and 
quality control processes (appendix).14 We used fully-
automated and validated neuroimaging segmentation 
algorithms based on FreeSurfer versions 5.1 or 5.3 
(appendix). To make sure FreeSurfer version did not 
affect the results,12 we did an additional analysis, adding 
version number as a covariate to our main model. For each 
participant, we computed intracranial volume and left 
and right volumes of the accumbens, putamen, pallidum, 
caudate, thalamus, amygdala, and hippo campus. For 
further analysis, we used the mean of the left and right 
volume. For an overview of single site subcortical 
structures, see appendix. Outliers were identified at above 
and below one and a half times the interquartile range 
per cohort and group (case and control) and were excluded 
(appendix).15
Differences in subcortical brain volumes and intracranial 
volume
By pooling available individual data from all cohorts in 
a mega-analysis, we were able to investigate as our 
primary outcome differences between cases and controls 
of subcortical volumes and intracranial volume. After 
excluding collinearity of age, sex, and intracranial 
volume (variance inflation factor <1·2) and normality 
testing, the mega-analysis of each subcortical volume 
was done with a linear mixed model with the package 
nlme in R (version 3.1-117). The model included 
diagnosis (case=1 and control=0) as a factor of interest, 
age, sex, and intracranial volume as fixed factors, and 
site as a random factor. In the analysis of intracranial 
volume, this variable was omitted as a covariate from the 
model. Handedness was added to the model to correct 
for possible effects of lateralisation, but was excluded 
from the model when there was no significant 
contribution of this factor. To calculate Cohen’s d effect 
size estimates, adjusted for age, sex, site, and intracranial 
volume, we used the t statistic from the factor diagnosis 
in the model. In a post-hoc analysis, left and right 
volumes were studied separately.
To make sure that no unobserved factor biased our 
analysis of case-control differences, a meta-analysis was 
also done by linear regression analysis for each volume 
and for each sample separately, taking age, sex, and 
intracranial volume into account. We characterised 
heterogeneity with the I² statistic. The R package metaphor 
(version 1.9-1) was used to do an inverse variance-weighted, 
random-effects meta-analysis, in accordance with other 
ENIGMA Working Groups (appendix).12,15
Effects of age
The prespecified secondary outcome of the effect of age 
on subcortical volume and intracranial volume was 
studied by running the above described model for 
groups stratified by age: in children aged 14 years or 
younger, adolescents aged 15–21 years, and adults aged 
22 years and older. We removed samples that were left 
with ten patients or fewer because of the stratification. 
Because the effects of age probably do not strictly 
follow a linear model, we report linear effects of age 
and the effect of age by diagnosis. More explorative 
modelling was done to better understand the effects 
Site, country of origin Total 
(n=3242)
Cases 
(n=1713)
Controls 
(n=1529)
Age
Men Women Men Women
ADHD-WUE Würzburg, Germany 118 32 30 26 30 39·7 (11·4)
ADHD-DUB1 Dublin, Ireland 75 27 9 31 8 22·3 (5·2)
ADHD-DUB2 Dublin, Ireland 20 16 4 ·· ·· 33·7 (10·2)
ADHD-Mattos Rio de Janeiro, Brazil 17 10 7 ·· ·· 22·9 (1·4)
ADHD200-KKI Baltimore, USA 94 15 10 41 28 10·2 (1·3)
ADHD200-NYU* New York, USA 260 115 36 54 55 11·5 (2·9)
ADHD200-Peking Peking, China 245 90 12 84 59 11·7 (2·0)
ADHD200-OHSU Oregon, USA 109 29 13 30 37 9·1 (1·3)
ADHD-UKA Aachen, Germany 181 95 7 53 26 11·2 (2·7)
Bergen-adultADHD Bergen, Norway 81 21 17 16 27 31·2 (6·7)
Bergen-SVG Bergen, Norway 54 20 5 20 9 10·1 (1·2)
DAT-London London, UK 56 27 0 29 0 15·8 (2·1)
IMpACT-NL Nijmegen, Netherlands 245 49 76 49 71 35·5 (11·4)
MGH-ADHD New York, USA 148 42 37 29 40 35·8 (12·0)
NICHE Utrecht, Netherlands 158 68 10 67 13 10·4 (2·00)
NYU ADHD New York, USA 80 22 18 22 18 31·6 (9·4)
UAB-ADHD Barcelona, Spain 198 82 21 64 31 25·8 (13·0)
ZI-CAPS Mannheim, Germany 35 17 5 7 6 12·7 (1·2)
ADHD-Rubia London, UK 77 44 0 33 0 14·0 (2·2)
NeuroImage-ADAM Amsterdam, Netherlands 182 73 24 57 28 17·2 (3·2)
NeuroImage-NIJM Nijmegen, Netherlands 178 89 50 23 16 16·9 (3·4)
NIH Bethesda, USA 502 168 83 168 83 10·0 (3·1)
MTA Irvine, USA 129 73 15 31 10 25·6 (1·4)
Data are n or mean (SD). For a more detailed description and references for the assessments and neuroimaging 
procedures, see appendix. *One patient was excluded because of a missing sex status.
Table 1: Overview of cohort characteristics by sample
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of age, by plotting of moving averages and use of 
fractional polynomials to fit non-linear models to the 
data (appendix).
Corrections for multiple comparisons for 32 tests 
(eight volumes and four groups: all, children, adolescents, 
and adults) were applied by use of a false discovery rate 
with q=0·05, resulting in a p value significance threshold 
of p=0·0156.
Effects of sex, psychostimulant medication, and clinical 
measures
In an exploratory analysis, we investigated the effects of 
sex on brain volume from the main model. To examine 
associations between previous psycho stimulant treatment 
and regional brain volume, the mega-analysis model was 
run again, including only patients with medication 
information available (appendix). To test whether acute 
effects of psychostimulant medication confounded 
possible brain-volume differences between participants 
with ADHD and healthy controls, we excluded patients 
treated with stimulants at the time of their participation in 
the study (participants receiving other types of treatment 
were retained). Additionally, as previous meta-analyses 
had shown an association between stimulants and brain 
volumes,5,6 we compared patients who had ever used 
stimulant medication to patients who had never used 
stimulant medication. We explored the effects of ADHD 
symptom scores and the presence or absence of comorbid 
disorders on those brain volumes that differed significantly 
between participants with ADHD and healthy controls 
(appendix).
Role of funding sources
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to 
all of the data and the final responsibility to submit 
for publication.
Cases (n=1713) Controls (n=1529) p value for diagnosis Cohen’s d (95%CI)* Other significant factors in the model
Accumbens 1652 1471 <0·0001† –0·15 (–0·22 to –0·08) Intracranial volume, site, age
Amygdala 1598 1463 <0·0001† –0·19 (–0·26 to –0·11) Sex, intracranial volume, site
Caudate 1659 1489 0·0014† –0·11 (–0·18 to –0·05) Intracranial volume, site, age
Hippocampus 1599 1436 0·0041† –0·11 (–0·18 to –0·03) Sex, intracranial volume, site
Pallidum 1651 1471 0·95 –0·00 (–0·07 to 0·07) Sex, intracranial volume, site, age
Putamen 1660 1497 <0·0001† –0·14 (–0·21 to –0·07) Sex, intracranial volume, site, age
Thalamus‡ 1405 1242 0·39 –0·03 (–0·04 to 0·11) Sex, intracranial volume, site, age
Intracranial volume 1693 1513 0·0065† –0·10 (–0·17 to –0·03) Sex, site, age
*Adjusted mean volumes of subcortical brain volumes by site are described in the appendix. †p values are significant at the false discovery rate corrected threshold of 
p=0·0156. ‡Thalamus volume was not available from the National Institutes of Health sample.
Table 2: Results of the mega-analysis of subcortical brain volumes in the total sample
Children (<15 years) Adolescents (15–21 years) Adults (>21 years)
Cases Controls p value for 
diagnosis
Cohen’s d 
(95% CI)
Cases Controls* p value for 
diagnosis
Cohen’s d 
(95% CI)
Cases Controls p value for 
diagnosis
Cohen’s d 
(95% CI)
Accumbens 810 827 0·0001† –0·19 
(–0·29 to –0·10)
323 224 0·61 –0·04 
(–0·22 to 0·12)
510 415 0·12 –0·10 
(–0·23 to 0·03)
Amygdala 767 820 0·0003† –0·18 
(–0·28 to –0·08)
321 226 0·12 –0·14 
(–0·31 to 0·03)
500 412 0·03 –0·14 
(–0·27 to –0·01)
Caudate 825 840 0·006† –0·13 
(–0·23 to –0·04)
324 224 0·28 –0·10 
(–0·27 to 0·07)
502 420 0·30 –0·07 
(–0·20 to 0·05)
Hippocampus 764 802 0·012† –0·12 
(–0·22 to –0·03)
320 225 0·006† –0·24 
(–0·42 to –0·08)
506 404 0·38 0·06 
(–0·07 to 0·19)
Pallidum 816 831 0·79 –0·01 
(–0·11 to 0·08)
321 223 0·78 0·02 
(–0·15 to 0·20)
506 412 0·51 0·04 
(–0·08 to 0·17)
Putamen 836 854 0·0002† –0·18 
(–0·28 to –0·09)
329 228 0·83 –0·02 
(–0·19 to 0·15)
499 416 0·23 –0·08 
(–0·21 to 0·05)
Thalamus‡ 604 616 0·89 0·01 
(–0·10 to 0·06)
288 202 0·74 0·03 
(–0·15 to 0·21)
503 416 0·28 –0·07 
(–0·20 to 0·06)
Intracranial 
volume
837 854 0·003† –0·14 
(–0·24 to –0·04)
330 229 0·13 –0·13 
(–0·30 to 0·04)
515 422 0·91 0·01 
(–0·12 to 0·06)
*Due to a sample size lower than ten, the data for the following cohorts in analysis of the adolescent group were omitted: ADHD-Mattos (n=2), ADHD-WUE (n=2), BergenAdultADHD (n=4), MTA (n=2), 
Niche (n=7), and ZI-CAPS (n=2). †p values are significant at the false discovery rate corrected threshold of p=0·0156. ‡Thalamus volume was not available from the National Institutes of Health sample.
Table 3: Results of the mega-analysis of subcortical brain volumes in the stratified age groups
Articles
314 www.thelancet.com/psychiatry   Vol 4   April 2017
Centre Zurich, University of 
Zurich, Zurich, Switzerland 
(Prof D Brandeis); ETH Zurich, 
Zurich, Switzerland 
(Prof D Brandeis); Trinity College 
Institute of Neuroscience, 
Dublin, Ireland (C Kelly); Center 
for the Developing Brain, Child 
Mind Institute, New York, NY, 
USA (M P Milham PhD); Center 
for Biomedical Imaging and 
Neuromodulation, Nathan Kline 
Institute for Psychiatric 
Research, Orangeburg, NY, USA 
(M P Milham); Division of Child 
and Adolescent Psychiatric 
Research, Nathan Kline Institute 
for Psychiatric Research, 
Orangeburg, NY, USA 
(Prof F X Castellanos); 
Department of Psychiatry 
and Psychotherapy, 
University Hospital, 
Otto-von-Guericke-University, 
Magdeburg, Germany 
(M Zentis, T Frodl PhD); 
Department of Translational 
Neuroscience, School for Mental 
Health and Neuroscience, 
Maastricht University, 
Maastricht, Netherlands 
(Prof K-P Lesch); Department of 
Psychiatry, Psychosomatic 
Medicine and Psychotherapy, 
University Hospital Frankfurt, 
Frankfurt, Germany 
(Prof A Reif MD); Departments of 
Cognitive Science, Psychiatry, 
Radiology, and Center for 
Human Development, 
University of California, 
San Diego, CA, USA
Results
We included data from 23 cohorts with a sample size of 
3242 (1713 participants with ADHD and 1529 healthy 
controls; table 1) and a median age of 14·0 (range 4–63) 
years. As shown in table 2, the mega-analysis indicated that 
participants with ADHD had significantly smaller volumes 
for the accumbens, amygdala, caudate, hippocampus, 
putamen, and intracranial volume. Post-hoc analyses for 
the subcortical regions showed these effects to be bilateral 
(appendix). No effect of FreeSurfer version or handedness 
was recorded (appendix).
Results of the case-control meta-analysis were largely 
similar to those of the mega-analysis, but volume 
differences for accumbens and hippocampus were not 
significant (appendix). Heterogeneity (I²) across samples 
was low to moderate; heterogeneity was highest for the 
hippocampus (appendix) and might be indicative of 
non-linear effects of study site for this structure.
Age-stratified analyses showed significant case-control 
differences in children for the accumbens, amygdala, 
caudate, hippocampus, putamen, and intracranial 
volume (table 3, figure 1). Effect sizes were higher in 
children than those for the entire sample. In the 
adolescent group, there was a significant case-control 
difference in the hippocampus (table 3). In adults, none 
of the case-control comparisons were significant. 
Figure 1 suggested an interaction effect for age-group 
and diagnosis on hippocampus volume; this was not 
statistically supported by linear interaction statistics 
(p=0·03; appendix). Exploratory modelling with moving 
averages also showed that the age effects cluster early in 
life, with older age participants attaining peak volumes 
in the ADHD group (figure 2). The moving averages 
also suggested a potential later onset of volume decrease 
in the ADHD group, most clearly seen in accumbens 
and putamen (figure 2). Sample sizes after age 50 years 
were small (appendix), and resulted in wider confidence 
intervals in the moving average analyses. The fractional 
polynomial analyses also supported different develop-
mental models for patients with ADHD and controls 
for amygdala, hippocampus, putamen, thalamus, and 
intracranial volume (appendix).
All but two subcortical structures, accumbens and 
caudate, showed effects of sex in the mega-analysis 
(table 2). None of the volumes showed differential sex 
effects for participants with ADHD and controls (table 2).
Information about medication use was available for 
1254 (73%) of 1713 participants with ADHD; 455 (27%) of 
1713 participants with ADHD were on psychostimulant 
medication (methylphenidate or amphetamine) at the 
time of scanning, with more than half (19 [83%] of 23) of 
the studies with a washout period of 24 h or 48 h 
(appendix); 799 (47%) of 1713 participants with ADHD 
were not taking stimulant medication at scan time. Case-
control differences in brain volumes after excluding 
participants on stimulant medication were similar in 
effect sizes to those observed in the main analysis 
(table 4).
For 719 (42%) of 1713 participants with ADHD, 
information was available on lifetime usage of stimulant 
medication. Of these, 82 (11%) participants had never 
taken stimulant medication, compared with 637 (89%) 
patients, who used stimulant medication somewhere in 
their lifetime for a period of more than 4 weeks. No 
differences in any of the volumes were recorded by 
directly comparing these two groups.
Meta-analysis of the correlation between ADHD 
symptom scores in cases and brain volumes showed no 
significant effects (p>0·02; appendix). Nor were there any 
significant correlations when only the childhood samples 
were used in the meta-analysis. Also, the observed case-
control brain volume differences were not explained by 
the presence of another comorbid psychiatric disorder 
(p>0·5; appendix).
Discussion
We report the largest study to date of brain volume 
differences between participants with ADHD and healthy 
individuals. Compared with previous meta-analyses, 
our study newly identified amygdala, accumbens, and 
hippocampus volumes to be smaller in participants with 
ADHD than in healthy controls, and extended earlier 
findings for reduced caudate and putamen volumes 
by showing those effects to be bilateral rather than 
unilateral.5,7 Significant volume differences had small 
effect sizes (ranging from d=–0·10 to d=–0·19) and the 
meta-analysis confirmed these results. Age stratification 
Figure 1: Cohen’s d effect sizes of differences between patients with ADHD and healthy controls for 
subcortical volumes and intracranial volume, for all patients, children only (<15 years), adolescents only 
(15–21 years), and adults only (>21 years)
Error bars denote standard error. *Significant after false discovery rate correction. †Nominally significant at p<0·05. 
ICV=intracranial volume. 
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Figure 2: The moving averages, corrected for age, sex, intracranial volume, 
and site for the subcortical volumes
Error bars denote standard error.
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showed that volume differences clustered in children and 
no differences were reported in adults. The volume 
differences were equally apparent in those treated with 
psychostimulant medication and in those naive to 
psychostimulants. Additionally, no correlations with 
quantitative scores of ADHD symptoms were reported 
in cases, nor did comorbidity with other psychiatric 
disorders explain the findings. All but two subcortical 
brain volumes were smaller in women; this is consistent 
with published literature.16
Our findings contain several important messages for 
clinicians. First, the data from our highly powered 
analysis confirm that patients with ADHD do have altered 
brains and therefore that ADHD is a disorder of the brain. 
This message is clear for clinicians to convey to parents 
and patients, which can help to reduce the stigma that 
ADHD is just a label for difficult children and caused by 
incompetent parenting. We hope this work will contribute 
to a better understanding of ADHD in the general public, 
and that it becomes as apparent as major depressive 
disorder, for example, that we label ADHD as a brain 
disorder. Second, finding the most pronounced effects in 
childhood and showing delayed peaks of subcortical 
volume maturation provides a relevant model of ADHD 
as a disorder of brain maturation delay. Third, the 
brain differences we have reported are not caused by 
any comorbid disorders, medication effects, or ADHD 
symptom severity, but are exclusively related to the 
ADHD diagnosis. Fourth, finding the largest effect in the 
amygdala is important because this region links ADHD 
to emotional regulation problems. Those symptoms are 
often present in patients with ADHD, but these disease 
characteristics have not (yet) been included into the 
official DSM criteria. Our work provides neurobiological 
support for the inclusion of this domain in the core 
ADHD phenotype, asking for more acknowledgement of 
the importance of emotional regulation problems in 
patients with ADHD.
Our findings for striatum volume reduction are 
consistent with present models of ADHD.17 Differences 
in caudate volume are the most consistent finding 
for ADHD,4–6 and smaller putamen volumes have been 
frequently reported.5–7 Our study provides robust effect 
size estimates for those structural differences and shows 
that effects are bilateral. Although identified before in 
one study,18 our findings extend the meta-analytics 
literature to the third striatal volume, the nucleus 
accumbens. We identified novel meta-analytical findings 
for the amygdala and hippocampus. Previous work in 
single studies had found effects in these structures,19–21 
but did not replicate in others.22,23 For amygdala volume, 
which showed the largest effect size in our study (d=–0·19 
in the whole cohort; d=–0·18 in children), and for 
accumbens, the scarcity of earlier meta-analytical 
evidence for its role in ADHD might be due to the fact 
that these are small structures, for which automatic 
segmentation does less well.24 A more highly powered 
analysis might therefore have been necessary to 
overcome the experimental inaccuracy of these measures. 
Previous work provides functional evidence for a role of 
amygdala, accumbens, and hippocampus in patients 
with ADHD. Dysfunction of the amygdala is associated 
with difficulties in recognition of emotional stimuli, in 
callous unemotional traits, and with emotional regulation 
in general.25,26 Difficulties in recognition of emotional 
stimuli, diminished emotional reactions to pleasant 
stimuli, and high levels of callous, unemotional traits 
have all been linked to ADHD,27–30 and amygdala volume 
has been associated with hyperactivity.19 The accumbens, 
with its prominent role in reward processing, is central 
to motivational and emotional dysfunction in patients 
with ADHD.17 The results of the hippocampus are less 
straight-forward, because there is not so much evidence 
for a deficit in long-term memory, the main function of 
the hippocampus, in patients with ADHD.31 However, 
there are also reports on the hippocampus having a role 
in the regulation of motivation and emotion, which is 
impaired in patients with ADHD.32
Importantly, effect sizes observed in our study were 
similar to those reported for other psychiatric disorders 
Currently not taking stimulants* Stimulant use in patients with ADHD
Cases 
(n=799)
Controls 
(n=1529)
Cohen’s d (95% CI) p value for diagnosis Never 
stimulant 
use (n=82) 
Ever stimulant 
use (n=637)
p value for positive vs 
negative for lifetime 
stimulant use
Accumbens 776 1484 –0·12 (–0·21 to –0·03) 0·0069 79 625 0·32
Amygdala 753 1474 –0·18 (–0·27 to –0·10) >0·0001 80 590 0·41
Caudate 777 1502 –0·10 (–0·19 to –0·01) 0·0248 80 627 0·15
Hippocampus 757 1446 –0·08 (–0·17 to 0·003) 0·063 80 593 0·69
Pallidum 776 1484 0·01 (–0·07 to 0·10) 0·74 79 621 0·26
Putamen 784 1508 –0·13 (–0·22 to –0·04) 0·0037 81 627 0·29
Thalamus 692 1253 –0·03 (0·04 to –0·12) 0·53 80 458 0·29
Intracranial volume 793 1512 –0·06 (0·04 to –0·16) 0·15 81 632 0·92
*Within this group, 152 patients were lifetime positive for the use of stimulant medication, 82 were lifetime negative; for 565 participants no lifetime information was available.
Table 4: Results of the exploration of the effect of medication on case-control differences
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analysed with the ENIGMA procedures, in particular 
major depression and bipolar disorder.12,33 The scale of the 
effects is consistent with expectations for a heterogeneous 
disorder such as ADHD. The specific pattern of findings 
might partially differentiate ADHD from the other 
psychiatric disorders analysed with similar procedures, ie, 
schizophrenia, bipolar disorder, and major depressive 
disorder.12,14,33 In particular, effects on caudate and putamen 
seem to be ADHD specific among the four disorders. 
However, as mostly adults were assessed for the other 
three disorders, formal analyses taking age into account 
will need to be done to make valid statements.
The results of the age-stratified analysis indicate that 
subcortical volume differences in ADHD are most 
prominent in children, and non-existent in adults. Our 
additional exploratory models suggest that this finding is 
not the entire story on age effects, although care in 
interpretation of this result is needed because of the 
cross-sectional design of this study. On the basis of our 
findings across different approaches, we propose a model 
of altered trajectories of subcortical volume in patients 
with ADHD. Our data suggest a delayed peak volume in 
participants with ADHD, which is reminiscent of earlier 
reports that showed altered velocity of cortical 
development in a longitudinal sample.34 This model 
should be confirmed by longitudinal analyses, especially 
because the childhood and adult ADHD samples 
included in this study represent different subgroups of 
the population: childhood ADHD samples include those 
who will later remit and those who will persist having 
ADHD in adulthood; the adult ADHD samples include 
only the latter. In addition to the delays in subcortical 
brain maturation at early age, our exploratory work 
tentatively suggests later onset of decreases in subcortical 
volumes beyond the fourth decade of life in ADHD. 
However, because sample sizes in our analysis dropped 
dramatically above age 25 years, and we had insufficient 
data to study age effects after 60 years, this work is 
hampered by not having sufficient patients per site to 
rule out site-biases in those age ranges. As long as ADHD 
in old age is still a blind spot in ADHD research, it will be 
difficult to test the validity of such findings.
Previous meta-analyses showed associations between 
the proportion of treated patients and right caudate and 
amygdala and uncus (an anterior extremity of the 
parahippocampal gyrus) volumes.5,6 In our analysis, in 
which we were able to compare treated to non-treated 
participants with ADHD directly in a sample more than 
four times larger than that of the samples in two previous 
meta-analyses,5,6 we did not confirm such associations with 
brain volume. Our findings support those of the most 
recent meta-analysis.6 However, because our study had a 
non-randomised, cross-sectional design, some caution in 
the interpretation of these results is warranted because the 
design of this study was not optimal to test for medication 
effects. Also, because both previous meta-analyses used 
voxel-wise maps, there is a possibility that the observed 
normalising effects of medication were too local to be 
picked up by volumetry.
We did not note associations between brain volumes 
and clinical measures, ie, comorbidity or ADHD 
symptom scores. The absence of an association with 
comorbidity suggests that the brain volume reductions 
are robustly linked to ADHD itself, rather than being a 
secondary phenomenon caused by comorbidity. The 
absence of significant associations between brain 
volumes and symptom ratings is not surprising, given 
that brain function is based on distributed networks of 
brain regions rather than individual brain regions.35 
Still, previous studies did find single volume–function 
associations,9,36 which we do not replicate here. We 
also could not replicate an earlier reported (modest) 
correlation of a total brain volume measure highly 
related to intracranial volume with ADHD symptom 
severity in a similarly sized population sample.10 Not 
finding effects of symptom scores might also be due to 
the heterogeneity of the instruments used for different 
cohorts in our study or differences in raters (ie, 
clinicians, teachers, and parents). Additionally, the 
sample size was halved in this case-only analysis, and 
the distribution of scores was skewed to the clinical 
range. In agreement with models of frontostriatal 
dysfunction in patients with ADHD, one hypothesis 
could be that cortical structures have a more important 
role in the severity of symptoms in these patients than 
the subcortical structures.13
A clear strength of this study is the sample size, being 
the largest mega-analysis and meta-analysis to date, with 
enough power to detect effects as small as d=0·08. Another 
strength is the harmonisation of segmentation protocols 
across all contribution sites, reducing imprecision caused 
by differences in methods. Nonetheless, diagnostic 
routines and acquisition of imaging data still differed 
between sites, a limitation contributing to heterogeneity 
across samples. A strength was also the opportunity for 
mega-analysis. Although effect sizes were similar to the 
meta-analysis, the mega-analysis allowed a more powerful 
detection of case-control volume differences. The mega-
analysis also enabled effects of age, sex, comorbidity, and 
medication to be studied, although accounting for site in 
these analyses might have somewhat masked age effects 
(as many studies had a restricted age range). Modelling 
age in a cross-sectional study is challenging but we have 
used several approaches to understand the effects of age. 
However, we should be cautious and interpret our findings 
as hypothesis-generating for future studies.
To conclude, these data are the first results of our 
worldwide collaboration and confirm and extend previous 
findings of reduced striatal volume in patients with 
ADHD. Optimisation of sample size and harmonisation 
of methods across studies allowed us to identify additional 
differences in amygdala and hippocampal volumes 
between cases and controls, potentially contributing to 
problems in emotional regulation, motivation, and 
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memory in patients with ADHD. Brain volume 
differences were most prominent in children. We invite 
interested researchers to join the next studies of the 
ENIGMA ADHD Working Group. In this way, we might 
optimally benefit from efforts already invested in 
individual studies to better understand this common yet 
still vexing disorder.
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